SMPL Stock: Price Thinks There’s No Future Beyond Quest
Quest, Atkins, OWYN, and Simply Good Foods’ Valuation Reset
Simply Good Foods (NASDAQ: SMPL) plunged from near $38 to about $13. Now its forward P/E is roughly 7.5x. Enterprise value plummeted to about 6.8x the company’s latest EBITDA guidance. After such a crash, those numbers pose an obvious question: For an asset-light branded consumer company that still generates positive cash flow and carries relatively modest leverage, has shares already priced in all of the bad news? Don’t get me wrong. That is a fair question to ask.
But it’s not the most important question. The biggest issue facing SMPL stock is how much of today’s earnings will stick. Plus, will investors pay for a temporarily impaired growth platform or a basket of brand assets entering secular decline?
SMPL Is Three Businesses, Not One Cash Flow
SMPL is a protein-snacking company on the surface. But economically, it is a basket of three businesses with varying levels of quality, growth and duration.
Quest is SMPL’s core asset. It produces roughly two-thirds of company revenue and most of its operating value. Atkins is an older brand that still churns out cash flow, but is losing relevance with consumers and retail shelf space. OWYN is a newly acquired brand whose growth turnaround is far from proven due to serious execution issues.
Putting all three businesses together on one income statement creates a distorted picture. Consolidated EBITDA still looks juicy. But not all of the assets producing that EBITDA should be valued equally.
Consider Quest, which serves as the load-bearing wall of the entire business. Within Quest, internals are increasingly bifurcated. Through fiscal 2026’s third quarter, total retail consumption for Quest brands was still growing slightly. Household penetration was also rising, which means the brand is not losing its ability to recruit consumers.
Dig deeper and you’ll see where problems are emerging. Traditional protein bar sales cratered by about 5%. Protein chip sales, however, surged roughly 17%. This isn’t just a shift among SKUs. Quest is trying to trade out its older growth engine — protein bars, where the category is increasingly fragmented and consumer novelty is waning — for a newer engine: protein chips.
If chips fail to grow and become a bigger part of the overall portfolio, Quest will move from growth asset into negative territory. Low-single-digit expansion would be toast. However, if chip sales continue to surge while bars slowly erode, Quest can still grow at a low-single-digit rate.
Atkins couldn’t be more different. Revenue was down approximately 22% in H1 fiscal 2026 as management aggressively cut back on marketing spending, allowing the dwindling brand to maintain healthy near-term margins. That margin profile is not indicative of better brand quality. Most of the story is that the company is no longer investing in its future. As advertising, promotional support and consumer acquisition budgets are slashed, near-term cash generation can look impressive even as household penetration, shelf space and the future revenue stream continue to decline. Atkins should be viewed far more as a finite duration annuity than a mature consumer franchise that deserves a perpetual multiple. The cash flow it generates today is very real, but it’s becoming cash that is used to subsidize the repair of other brands instead of being invested into its own future.
OWYN Is Not Just an Impairment Story
SMPL paid roughly $282 million to acquire plant-based protein shake brand OWYN in 2024, based on the belief that its scale with mass-market retailers like Walmart, Amazon would help scale a brand that had historically sold strongest through natural and specialty outlets. The rationale made sense on paper. OWYN not only gave SMPL a foothold in ready-to-drink protein, but also appealed to dairy-free, allergen-conscious, and vegetarian consumers looking for a plant-based protein snack. However, timing is everything in grocery and OWYN ran into product fit issues — namely taste and texture — during the most crucial period of its expansion, alongside lackluster marketing support. First impressions matter enormously in food, and new consumers were turned off while retail velocity came in well below expectations, threatening some of the distribution gains OWYN had recently made. Approximately 21 months after acquisition, SMPL wrote down about $187 million against OWYN, amounting to roughly two-thirds of the brand’s original purchase price. The impairment itself is non-cash, so while noteworthy is not the main issue. More important is that OWYN exposed a flaw in a strategic thesis that up until that point had propped up SMPL’s valuation higher: Buying a smaller brand and inserting it into the company’s distribution channels is not a guarantee of growth. Quest had already proven product-market fit and was enjoying strong retail velocity prior to being acquired by SMPL. SMPL accelerated growth of something that had already been proven to work. OWYN was rapidly introduced into mass channels before its product quality had been stabilized and acceptance from consumers had been established. Both are characterized as “acquire and scale” deals on paper, but the risk profiles were vastly different. SMPL’s asset-light advantage works both ways. Third-party production and low fixed costs allow SMPL to turn profit into free cash flow during healthy years. But because production is outsourced, product consistency is only guaranteed to the extent that co-manufacturers don’t alter the recipe. Access to shelf space is dictated by large retailers who can replace poorly performing brands overnight. Walmart and Amazon account for nearly half of SMPL’s sales, and retail contracts typically don’t include minimum guarantees. Every product has to earn its shelf space through velocity at the store level. Not only is SMPL selling protein bars; it is selling retailers and consumers on why its products deserve to stay on the shelf. There are capital efficiency benefits to an asset-light structure, but meaningful control over the business is effectively outsourced as well.
The Current Valuation Is Pricing Stability, Not a Recovery
At roughly $13.17 per share, SMPL is trading with an enterprise value of about $1.5 billion. Based on adjusted EBITDA guidance of $220 million to $225 million, the enterprise trades for approximately 6.8x EV/EBITDA. That’s not a random number. For an asset-light company that should be able to convert roughly 68% of EBITDA to unlevered free cash flow, 10% required return and no long-term growth literally requires a fair multiple of approximately 6.8x. Less mathematically, the market is not pricing SMPL out of existence, but it’s not pricing any real recovery either. It’s saying that the company can tread water, but may not grow.
That’s why an “only” forward earnings multiple of seven or eight times isn’t a buying opportunity by itself. The market still believes that Quest has some brand strength, that the asset-light model can produce cash, and that the balance sheet doesn’t pose an immediate threat to the company’s survival. On the other hand, it’s apparently not assigning much value to an OWYN recovery or stabilization, an Atkins return to positive growth, or even broad-based growth at Quest. The critical factor isn’t the multiple itself, but the earnings base to which that multiple is applied. If somewhere near $220 million of EBITDA is likely to be a durable trough, then the stock is probably trading right around fair value. But if gross margins normalize and Quest continues to expand, then earnings could start to turn higher and today’s prices would look attractive. If Quest enters a sustained downturn, however, even 6.8x EBITDA might be too rich.
Debt-Funded Buybacks Highlight a Process Issue
SMPL repurchased roughly 9.6 million shares for approximately $188 million during the first six months of fiscal 2026 at an average price of about $19.62 per share. At the same time, it added a new $150 million term loan, which will increase annual interest expense by about $10 million. To say that taking out debt to buy back stock was dumb just because the stock is now trading below the buyback price would be outcome bias. Still, SMPL transformed what should have been a highly uncertain valuation call into a capital allocation decision with effectively no financial stop loss.
What’s most interesting about the timing is that on January 6, 2026, the board decided to increase the buyback authorization by $200 million. On January 8, SMPL reaffirmed full-year guidance. On January 18, CEO Geoff Tanner resigned. On January 20, former CEO Joe Scalzo returned to the company, and management reaffirmed guidance for the second time. At the point where buybacks were being increased and the company was publicly reaffirming its conviction, internal doubts about execution had apparently reached a point where the CEO needed to be replaced. Personally, I don’t think that implies malicious intent or a hidden agenda. In fact, the public statements weigh more heavily in favor of management sincerely believing the stock to be undervalued than believing anything else. But it does seem clear that the company did not have a good process for slowing or discontinuing buybacks as new information became available. Debt-funded buybacks can be value accretive when earnings are stable. Balance sheet capacity should be viewed as excess cash when it’s being used to retire shares. When you’re in trouble, it’s ammunition for brand repair, marketing support, and the option to wait until you have better information.
Conclusion
I estimate SMPL’s fair value under existing operating conditions to be around $13.50 to $14.50 per share. That implies that the stock isn’t terribly overvalued, but it also doesn’t leave much room for error. You’re essentially paying full value for Quest’s current cash generation and leftover harvest value at Atkins, while getting OWYN’s turnaround potential, future Quest chips expansion, and strategic transaction potential as lottery tickets.
For that reason, SMPL feels like a turnaround play that hasn’t yet earned its turnaround rather than a consumer compounder that can be aggressively bought just because the valuation looks low. The current price assumes that the bleeding will stop, but doesn’t give you much margin for error if efforts to repair the broader business don’t work. I’d want either a lower price to buy or better evidence that the operating trajectory is changing rather than simply watching the stock price fall.
Disclaimer: This article is intended for informational, research, and educational purposes only. It should not be considered investment advice, a recommendation to buy or sell any securities, an offer to buy or sell, or personalized financial advice. The information presented may be incomplete or inaccurate and may change at any time without notice. You should conduct your own due diligence and consult with a licensed financial professional before making any investing decisions. Your decisions should be based on your personal financial situation, investment goals, time horizon, and risk tolerance. I may buy or sell securities mentioned in this article at any time.